Rare Disease Report

A New Era in Hearing Loss Protection For Cancer Patients

MAY 03, 2017
David Freyer, DO

David Freyer, DO, of the Children's Hospital of Los Angeles praises the clinical trial he was involved with showing that the administration of sodium thiosulfate (STS) in pediatric cancer patients receiving cisplatin reduced the number of patients developing hearing loss. 
This landmark trial was the first of its kind and Dr Freyer is looking forward to future studies in this field to provide options for patients, especially pediatric patients, undergoing platinum-based cancer therapy. 


Freyer DR, Chen L, Krailo MD, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18:63-74. doi: 10.1016/S1470-2045(16)30625-8

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.